RC
HRMY icon

Renaissance Capital’s Harmony Biosciences HRMY Stock Holding History

Renaissance Capital’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,622
Closed -$282K – 80
2023
Q1 		$282K Sell
8,622
-913
-10% -$41.6K 0.21% 75
2022
Q4 		$525K Buy
+9,535
New +$524K 0.41% 63

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Capital's HRMY Position: Q2 2023 in Review

Renaissance Capital sold out of Harmony Biosciences (HRMY) in Q2 2023, closing a stake of 8,622 shares — an estimated $282K sold.

Renaissance Capital first reported a position in HRMY in Q4 2022 and held it in 2 quarters. The position peaked at $525K in Q4 2022. 211 funds tracked by Wall St. Rank hold HRMY as of Q2 2023.

  • Renaissance Capital reported no remaining Harmony Biosciences position as of Q2 2023 after selling out during the quarter.
  • Renaissance Capital sold 8,622 Harmony Biosciences shares in Q2 2023, an estimated $282K.
  • Renaissance Capital first reported a position in Harmony Biosciences in Q4 2022 and held it in 2 quarters.
  • Renaissance Capital's Harmony Biosciences position peaked at $525K in Q4 2022.
  • 211 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2023.

Based on Renaissance Capital's 13F filing for Q2 2023, filed 17 Jul 2023.